"As a world class leader, Linear Clinical Research (Linear) is a purpose built state-of-the-art, clinical trials facility operating out of QEII Medical Centre in Perth, Western Australia. Conceived as a focal point for Australian clinical and medical research, Linear is making innovative therapies available to our local community. We’ve come a long way since Linear’s inception in 2010 as a visionary collaborative venture between The Harry Perkins Institute and the Departments of Health and Commerce. A regular winner of the Australian Export Awards in Canberra and featured regularly on major TV stations, Linear has tremendous opportunities for researchers and the general community to help nurture medical breakthroughs."

During the past decade, Linear Clinical Research conducted 133 clinical trials. In the 10-year time frame, 133 clinical trials started and 16 clinical trials were completed, i.e. on average, 12% percent of trials that started reached the finish line to date. In the past 5 years, 76 clinical trials started and 14 clinical trials were completed. i.e. 18.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Linear Clinical Research" #1 sponsor was "BeiGene" with 14 trials, followed by "Arrowhead Pharmaceuticals" with 8 trials sponsored, "Atridia Pty Ltd." with 7 trials sponsored, "Genentech, Inc." with 5 trials sponsored and "Hoffmann-La Roche" with 5 trials sponsored. Other sponsors include 106 different institutions and companies that sponsored additional 89 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Linear Clinical Research" #1 collaborator was "Novotech (Australia) Pty Limited" with 5 trials as a collaborator, "Linear Clinical Research" with 4 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "Linear Clinical Research" are "Advanced Solid Tumor" (10 trials), "Healthy Volunteers" (8 trials), "Advanced Solid Tumors" (7 trials), "Melanoma" (6 trials) and "Colorectal Cancer" (5 trials). Many other conditions were trialed in "Linear Clinical Research" in a lesser frequency.

Most popular intervention types in "Linear Clinical Research" are "Drug" (133 trials), "Biological" (20 trials) and "Other" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (31 trials), "Atezolizumab" (6 trials), "Nivolumab" (6 trials), "Tislelizumab" (5 trials) and "Abemaciclib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Linear Clinical Research" are 142 trials for "All" genders, 5 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are 60 active trials in "Linear Clinical Research". 1 are not yet recruiting, 40 are recruiting, 18 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 76 completed trials in Linear Clinical Research, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Linear Clinical Research, 121 "Phase 1" clinical trials were conducted, 52 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".